RT Journal Article
T1 A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study.
A1 Prusakov, Pavel
A1 Goff, Debra A
A1 Wozniak, Phillip S
A1 Cassim, Azraa
A1 Scipion, Catherine E A
A1 Urzúa, Soledad
A1 Ronchi, Andrea
A1 Zeng, Lingkong
A1 Ladipo-Ajayi, Oluwaseun
A1 Aviles-Otero, Noelia
A1 Udeigwe-Okeke, Chisom R
A1 Melamed, Rimma
A1 Silveira, Rita C
A1 Auriti, Cinzia
A1 Beltrán-Arroyave, Claudia
A1 Zamora-Flores, Elena
A1 Sanchez-Codez, Maria
A1 Donkor, Eric S
A1 Kekomäki, Satu
A1 Mainini, Nicoletta
A1 Trochez, Rosalba Vivas
A1 Casey, Jamalyn
A1 Graus, Juan M
A1 Muller, Mallory
A1 Singh, Sara
A1 Loeffen, Yvette
A1 Pérez, María Eulalia Tamayo
A1 Ferreyra, Gloria Isabel
A1 Lima-Rogel, Victoria
A1 Perrone, Barbara
A1 Izquierdo, Giannina
A1 Cernada, María
A1 Stoffella, Sylvia
A1 Ekenze, Sebastian Okwuchukwu
A1 de Alba-Romero, Concepción
A1 Tzialla, Chryssoula
A1 Pham, Jennifer T
A1 Hosoi, Kenichiro
A1 Consuegra, Magdalena Cecilia Calero
A1 Betta, Pasqua
A1 Hoyos, O Alvaro
A1 Roilides, Emmanuel
A1 Naranjo-Zuñiga, Gabriela
A1 Oshiro, Makoto
A1 Garay, Victor
A1 Mondì, Vito
A1 Mazzeo, Danila
A1 Stahl, James A
A1 Cantey, Joseph B
A1 Monsalve, Juan Gonzalo Mesa
A1 Normann, Erik
A1 Landgrave, Lindsay C
A1 Mazouri, Ali
A1 Avila, Claudia Alarcón
A1 Piersigilli, Fiammetta
A1 Trujillo, Monica
A1 Kolman, Sonya
A1 Delgado, Verónica
A1 Guzman, Veronica
A1 Abdellatif, Mohamed
A1 Monterrosa, Luis
A1 Tina, Lucia Gabriella
A1 Yunis, Khalid
A1 Rodriguez, Marco Antonio Belzu
A1 Saux, Nicole Le
A1 Leonardi, Valentina
A1 Porta, Alessandro
A1 Latorre, Giuseppe
A1 Nakanishi, Hidehiko
A1 Meir, Michal
A1 Manzoni, Paolo
A1 Norero, Ximena
A1 Hoyos, Angela
A1 Arias, Diana
A1 Sánchez, Rubén García
A1 Medoro, Alexandra K
A1 Sánchez, Pablo J
A1 Global NEO-ASP Study Group, 
K1 Antibiotics
K1 Antifungal
K1 Global point prevalence study
K1 Neonatal antimicrobial stewardship
K1 Neonatal infection
AB Global assessment of antimicrobial agents prescribed to infants in the neonatal intensive care unit (NICU) may inform antimicrobial stewardship efforts. We conducted a one-day global point prevalence study of all antimicrobials provided to NICU infants. Demographic, clinical, and microbiologic data were obtained including NICU level, census, birth weight, gestational/chronologic age, diagnoses, antimicrobial therapy (reason for use; length of therapy), antimicrobial stewardship program (ASP), and 30-day in-hospital mortality. On July 1, 2019, 26% of infants (580/2,265; range, 0-100%; median gestational age, 33 weeks; median birth weight, 1800 g) in 84 NICUs (51, high-income; 33, low-to-middle income) from 29 countries (14, high-income; 15, low-to-middle income) in five continents received ≥1 antimicrobial agent (92%, antibacterial; 19%, antifungal; 4%, antiviral). The most common reasons for antibiotic therapy were "rule-out" sepsis (32%) and "culture-negative" sepsis (16%) with ampicillin (40%), gentamicin (35%), amikacin (19%), vancomycin (15%), and meropenem (9%) used most frequently. For definitive treatment of presumed/confirmed infection, vancomycin (26%), amikacin (20%), and meropenem (16%) were the most prescribed agents. Length of therapy for culture-positive and "culture-negative" infections was 12 days (median; IQR, 8-14) and 7 days (median; IQR, 5-10), respectively. Mortality was 6% (42%, infection-related). An NICU ASP was associated with lower rate of antibiotic utilization (p = 0·02). Global NICU antibiotic use was frequent and prolonged regardless of culture results. NICU-specific ASPs were associated with lower antibiotic utilization rates, suggesting the need for their implementation worldwide. Merck & Co.; The Ohio State University College of Medicine Barnes Medical Student Research Scholarship.
YR 2021
FD 2021-01-29
LK http://hdl.handle.net/10668/17119
UL http://hdl.handle.net/10668/17119
LA en
DS RISalud
RD Apr 8, 2025